Innovent Bio (01801.HK): Accelerating Internationalization and Commercialization to Unlock Upside Potential

We believe that, alongside the global validation of first-in-class proof-of-concept (POC) data for the innovative global product IBI363 (PD-1/IL-2α-bias) and its continued international verification, the GLP-1/GCGR dual agonist Mazdutide and IBI3

Zheshang Securities16:07

Goldman Sachs: Remains bullish on visibility-driven CDMOs; closely monitoring early signs of market bottoming

Goldman Sachs published a research report noting that since the beginning of 2026, China’s healthcare sector has delivered muted performance, with offshore and onshore markets posting returns of approximately -3% and 0%, respectively. However, dispersion in stock performance has widened significantly, with the CRO/CDMO segment up roughly 8% year-to-date and biotech stocks rising about 6%, primarily driven by improved earnings visibility and expectations surrounding key product data. The firm believes the market is increasingly rewarding companies demonstrating strong execution, sustainable profitability, and greater asset-level visibility. Heading into mid-2026, the firm maintains its preference for CDMO companies due to their favorable earnings cycle, while selectively positioning in

AASTOCKS12:26

Zieziula Gary Joseph reduced his stake in Innovent Bio (01801) by approximately 43,400 shares at an average price of about HK$87.84 per share.

On May 14, Zieziula Gary Joseph sold 43,431 shares of Innovent Bio (01801.HK) at HK$87.8416 per share, for a total transaction value of approximately HK$3.815 million.

Zhitong FinanceMay 19 19:43

Express News | According to information disclosed by the Hong Kong Exchange, BlackRock reduced its stake in Innovent Bio's H shares from 5.13% to 4.93% on May 13.

BreakingsMay 19 17:09

Hong Kong Stock Market Midday Review | Hang Seng Index fell 0.87% in the morning session, while the robotics sector surged against the trend.

Tesla's third-generation humanoid robot, Optimus V3, is expected to debut by mid-year, with formal production slated to commence in July-August 2026. Product testing is proceeding steadily, and the robot is projected to be deployed in external application scenarios by 2027. The robotics industry has now entered the mass-production competition phase.

Zhitong FinanceMay 15 12:00

Innovent Bio's stock price fell during the morning session as founder Dechao Yu recently sold shares, cashing out approximately HKD 1.21 billion.

Innovent Bio (01801) fell more than 8% in early trading. As of the time of writing, it dropped 7.61%, trading at HKD 80.1, with a turnover of HKD 8.45 billion.

Zhitong FinanceMay 15 10:33